BMI-1, a member of the Polycomb group of gene family, is essential for the self-renewal of hematopoietic, neural and cancerous stem cells.
1 BMI-1 is highly expressed in malignancies like B cell non-Hodgkin lymphoma, Hodgkin's lymphoma, colorectal carcinoma, liver carcinoma, non-small cell lung cancer, breast carcinoma and medulloblastoma. Interestingly, the study of BMi-1 knockout mice revealed that BMi-1 is indispensable for the self-renewal of both leukemic and normal hematopoietic stem cells. 2 In addition to its vital role in stem cell self-renewal, BMI-1 regulates the proliferative output of primitive hematopoietic progenitors in a critical manner. 1 We reported previously BMI-1 as a marker of disease progression in cases of myelodysplastic syndrome (MDS). 3 Therefore, we assumed that BMI-1 expression could be used to predict the prognosis of patients with acute myeloid leukemia (AML) and thus could serve as a tool to tailor therapy for this disease. This is the first study, in which flow cytometry was used to determine the expression of BMI-1 in AML blasts of human subjects.
We studied bone marrow (BM) samples (except two from peripheral blood (PB) and granulocytic sarcoma patient from the lymph node) obtained from 64 patients with newly diagnosed AML (Supplementary Tables 1 and 2 ). According to the Helsinki declaration, informed consent was obtained from the patients and donors (used as control), and an institutional review board approved the study. AML M3 patients were excluded from this study, due to their different disease biology and different treatment strategy. All cases of de novo AML were diagnosed as per the FAB criteria. Granulocytic sarcoma was diagnosed using lymph node biopsy. Secondary AML (MDS-AML or t-AML) was diagnosed according to the revised recommendations of the international working group on AML. 4 Complete remission (CR), partial remission , overall survival (OS), relapse-free survival (RFS) and remission duration (RD) were defined as per recommendations of the same group. 4 BM blasts p5%, absolute neutrophil count X1000 ml and platelet count X100 000 ml were the criteria for CR. Cytogenetic remission or molecular remission was not used to define CR. Flow cytometry with appropriate antibody was performed to confirm the diagnosis and morphologic leukemia-free state. Survival was measured from the date of diagnosis to the date of death or last follow-up. 
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To calculate cancer-specific survival (CSS), only deaths from the disease being studied were counted and treatment-related mortality was considered as an event. Also included in the evaluation were patients with reduced induction therapy owing or more) or stem cell transplantation was considered as highly intensive therapy (TI-4). Sixty percent dose of Ara-C and IDA/ DNR as treatment intensity-2 (TI-2) and less than this were stratified as treatment intensity-1 (TI-1). IDA 12 mg/m 2 or DNR 50 mg/m 2 and Ara-C 100 mg/m 2 were considered as standard induction regimen, whereas IDA/DNR (the same dose as standard induction regimen) plus Ara-C 200 mg/m 2 for three courses were considered standard consolidation regimen.
Karyotyping was carried out at diagnosis using standard G-banding with Wright's staining. Abnormalities were defined according to CALGB. 5 Complex karyotype with t(8; 21), inv(16) or t(16; 16) was considered favorable. A normal diploid karyotype or any other karyotypic abnormalities not defined by CALGB were evaluated as intermediate. Detection of fmsrelated tyrosine kinase 3 internal tandem duplication (FLT3-ITD) and mixed lineage leukemia partial tandem duplication (MLL-PTD) were carried out according to the published methods. 6, 7 We subjected fresh and/or cryopreserved mononuclear BM cells (except two from PB and granulocytic sarcoma patient from the lymph node) from patients to two-color staining with anti-CD34 antibody conjugated with phycoerythrin (PE) and anti-Bmi-1 monoclonal antibody with goat anti-mouse IgG antibody-FITC. 3 The BrdU incorporation assay was performed using BrdU Flow kit (BD Pharmingen, San Diego, CA, USA). According to the instruction manual, cells were stained with APC-fluorescent anti-BrdU and monoclonal anti-Bmi-1 antibody followed by secondary antibody for Bmi-1 antibody (described above). The staining of total DNA was carried out with 7-amino-actinomycin D (7-AAD) and the cells were subjected for flow cytometric analysis.
Statistical analyses were performed using the software package SPSS/Win version 11.5(SPSS Inc., Chicago, IL, USA). The correlation between BMI-1 expression and other prognostic factors was evaluated with Spearman's rank correlation test and/ or the w 2 test. Survival curves were drawn using the KaplanMeier method. A log-rank test was employed to compare OS, RFS, RD or CSS pattern of two or more groups. Prognostic variables with Pp0.3 in the univariate analysis were entered in the multivariate model. Pp0.05 was considered significant for both univariate and multivariate analyses. Cox's, multiple regression based on proportional hazard model was applied with a backward step-wise algorithm to identify factors affecting OS, RFS, RD and CSS.
To determine BMI-1 protein expression, we selected five AML cell lines, KG-1, Mono-7, HL-60, HEL and U-937, originating from M6, M0 (originated from MDS), M3, M6 and promonocytic leukemia, respectively. The level of expression was detected by immunoblot analysis ( Figure 1A) . By flow cytometry, very strong BMI-1 expression was seen in CD34 þ KG-1 (98.94%) and Mono-7 (97.75%) cells. CD34 -HEL, HL-60 and U-937 cells had variable levels of expression (42.68%, 81.79% and 90.10%, respectively) (Supplementary Figure 1) . Actively proliferating T cells have two populations; one is negative and the other is positive. We confirmed that the BMI-1 protein expression of all cell lines detected by flow cytometry was almost consistent with the intensity detected by immunoblotting. To find out whether BMI-1 expression has any relation with leukemic cell proliferation or not, we conducted BrdU experiment in the acute promonocytic leukemic cells of U-937. Figure 1B demonstrates that 5.65% of BMI-1-negative cells and 21.90% of cells with the lower intensity of BMI-1 incorporated BrdU, whereas 92.61% cells with the higher intensity incorporated BrdU. These results indicated that BMI-1 expression is not only related to leukemic cell self-renewal, but also provides potential for leukemic cell proliferation. We considered that in AML patients, both BMI-1
þ and BMI-1 þ CD34 -blasts could include proliferating and/or self-renewalling blasts. As described in Table 1 and Figure 1C , AML blasts, both positive and negative for CD34, expressed BMI-1.
Percentage of BMI-1 expression in leukemic cells was analyzed in 64 patients with AML-M0 (n ¼ 4), M1 (n ¼ 12), M2 (n ¼ 13), M4 (n ¼ 10), M5 (n ¼ 6), granulocytic sarcoma (n ¼ 1), MDS-derived AML (n ¼ 11) and therapy (t)-related AML (n ¼ 7). Among all the patients, 42 were male and 22 were female with a median age of 64.5 years. The overall CR rate was 59.36%. Median follow-up time for patients achieving CR was 10.63 (range, 0.97-64.64) months. Median OS for all patients was 12.25 (range, 0.10-65.57) months. The probability of surviving 5 years for all the patients was 17.6676.81%. The mean, median and range of BMI-1 expression (%) were 54.48, 54.58 and 0.55-100, respectively. Figure 1D shows the mean BMI-1 expression in different FAB subtypes. Age, sex, FAB subtype, or secondary AML was not correlated with BMI-1 expression, although the CD34 positivity (correlation coefficient, 0.421, P ¼ 0.001), and unfavorable karyotype (correlation coefficient, 0.281, P ¼ 0.025) had weak but significant correlation. Sawa et al. 8 have reported that AML M0 patients have higher BMI-1 expression. They used BM mononuclear cells and employed an RT-PCR approach. Recent evidence states that BMI-1 protein is a substrate of ubiquitination, 1 and can be modified in a posttranslational manner. Therefore, the difference between protein and RNA expression levels of BMI-1 might lead to the inconsistency of our results with their findings.
On the basis of median value of BMI-1 expression (54.58%), we divided the patients into two groups and analyzed their survival. We found that the cutoff level (55%) using the median correlates well with prognosis. Table 1 shows the distribution of the patients according to BMI-1. Table 2 summarizes the results of univariate and multivariate analyses for OS, RFS and RD. Patients with lower BMI-1 positivity (p55%, n ¼ 33) had significantly longer OS (P ¼ 0.0001), CSS (P ¼ 0.0000), RFS (P ¼ 0.0072) and RD (P ¼ 0.0065) when compared to the patients with higher BMI-1 (455%, n ¼ 31) (Figure 2A (a, b, c  and d ), respectively). By Cox's multiple regression based on proportional hazard model, BMI-1 expression retained the significance for OS (P ¼ 0.000), CSS (P ¼ 0.000), RFS (P ¼ 0.047) and RD (P ¼ 0.047).
Among the patients with normal karyotype (n ¼ 28), patients with lower BMI-1 expression (n ¼ 17) achieved better OS (P ¼ 0.0020) ( Figure 2B (a) ), CSS (P ¼ 0.0002), RFS (P ¼ 0.0194), and RD (P ¼ 0.0123) ( Figure 2B (b) ) when compared to those with higher BMI-1. Furthermore, among all of the patients with intermediate karyotype (n ¼ 43), patients with lower BMI-1 expression (n ¼ 27) had significantly higher OS (P ¼ 0.0025) ( Figure 2B (c) ), CSS (P ¼ 0.0001), RFS (P ¼ 0.0017) and RD (P ¼ 0.0013) ( Figure 2B (d) ). Multivariate analysis for OS of the patients with intermediate karyotype, showed the significance of BMI-1 expression (P ¼ 0.003) and age over 60 (P ¼ 0.001), whereas AML type, karyotype (whether normal or not), treatment intensity and WBC count failed to be significant. In addition, by Cox's multiple regression based on proportional hazard model for intermediate karyotype, BMI-1 expression was significant for CSS (P ¼ 0.000), RFS (P ¼ 0.000) and RD (P ¼ 0.001).
Among the patients with secondary AML (n ¼ 18), patients with lower BMI-1 expression (n ¼ 8) had statistically nonsignificant (P ¼ 0.2275), but better OS. Among the patients with de novo AML (n ¼ 46), patients with lower BMI-1 expression (n ¼ 25) had significantly higher OS (P ¼ 0.0008), CSS (P ¼ 0.0001), RFS (P ¼ 0.0182) and RD (P ¼ 0.0176). By multi-variate analysis for OS, BMI-1 expression (P ¼ 0.002) and age over 60 (P ¼ 0.000) retained significance whereas karyotype, treatment intensity and WBC count did not. Furthermore, BMI-1 expression retained significance by Cox's hazard model for CSS (P ¼ 0.000), RFS (P ¼ 0.000) and RD (P ¼ 0.000). Therefore, BMI-1 expression would be useful to stratify patients with 
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Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NR, non-remission; t-AML, therapy related AML; TI, treatment intensity; TRM, treatment-related mortality; WBC, white blood cell. de novo AML. Owing to the significance of age and BMI-1 in all analyses of survival done in this study, we conducted KaplanMeier analysis according to BMI-1 stratified by age. As expected, BMI-1 was a useful predictor in both the age groups for OS (ageo60 (P ¼ 0.0570) and age460 (P ¼ 0.0013), respectively) and RD (ageo60 (P ¼ 0.0469) and age460 (P ¼ 0.1095)) (Supplementary Figure 2) .
In the group of patients with higher BMI-1 with normal karyotype, 27.3% patients (three out of 11) had FLT3-ITD positivity, whereas among the patients with lower BMI-1 expression, only 5.9% had FLT3-ITD (1 out of 17) (Supplementary Figure 3 ). Nineteen patients with normal karyotype and in total 29 patients with intermediate karyotype could be analyzed for the detection of MLL-PTD. Out of four patients with normal karyotype and higher BMI-1, one was positive for MLL-PTD, whereas, in case of patients expressing lower BMI-1 and normal karyotype, out of 15 patients, only one was positive for MLL-PTD (Supplementary Figure 3) . In addition, among the patients with intermediate karyotype with karyotypic abnormality, one patient was found to be positive for FLT3-ITD, and the other for MLL-PTD.
We revealed that the expression of BMI-1 is an independent prognostic factor for OS, CSS, RFS and RD in AML. The significance of BMI-1 expression is evident in the univariate and multivariate analyses. It is clear that patients whose leukemic blasts express lower levels of BMI-1 can expect, together with higher chance of achieving CR, longer RD and better RFS, CSS and OS. In contrast, patients with higher BMI-1 expression have less chance of achieving CR, higher chance of relapse and reduced duration of survival. Karyotype has been known as a very strong predictor of OS and achievement of CR. 5 In this study, by using univariate analysis, karyotype was significant for OS, CSS, but not significant for RFS and RD. However, in all of the multivariate analyses karyotype failed to attain significance. Among the total 64 patients, median age of the patients was 64.5, and 38 patients were age 460. By univariate analysis, survival probability of the patients with age 460 is 0.0% at 4 years. Among the patients with favorable karyotype only two patients could be treated with HDAC. Therefore, not only because of number of patients with favorable and unfavorable karyotype, but also and may be more importantly owing to limiting factors of age and suboptimal treatment of the patients with favorable karyotype, karyotype failed to attain significance by multivariate analyses in this study. However, by univariate analysis BMI-1 expression was significant for all of the survival analyses among the patients with normal karyotype. Moreover, in this study, the majority of the patients (n ¼ 43) had intermediate karyotype, and BMI-1 expression was significant by both univariate and multivariate analyses for OS, CSS, RFS and RD of the patients with intermediate karyotype. Therefore, BMI-1 expression could be useful for further risk stratification of the patients with normal and intermediate karyotype.
In leukemia, sequential acquisition of point mutations and karyotypic changes leads towards the constitutive activation of proto-oncogenes and the loss of function of tumour-suppressor genes. Mutational analysis revealed that FLT3-ITD and/or MLL-PTD identifies patients with bad prognosis among the patients with normal karyotype. 6, 7 In this study, in the group of patients with normal karyotype, patients with higher BMI-1 expression had higher percentage of FLT3-ITD and/or MLL-PTD compared to the patients with lower one. Moreover, unfavorable karyotype had weak but significant correlation with BMI-1 expression. BMI-1 containing Polycomb-mediated gene silencing works through post-translational modification of histone. 1 The state of compaction of the chromatin fibre controls DNA accessibility and therefore plays a crucial role in establishment, maintenance and propagation of distinct patterns of gene expression. 1 Therefore, BMI-1 expression and predictive value of BMI-1 on prognosis might make it a beautiful focus for target therapy development in future.
Among the patients with higher BMI-1 expression, only three patients were alive until the last follow-up day. Two of them were treated with HDAC, and one has been followed up for 5 months. Although higher BMI-1 is a bad prognostic factor, HDAC could be useful in some cases. Patients with lower BMI-1 expression had higher CR rate (69.70% versus 51.61%) and tendency to achieve CR with reduced drug dosage, because six patients with lower BMI-1 expression achieved CR with 60% dosage of standard chemotherapy (TI-2). However, several patients with lower expression did not achieve CR. This could be owing to role of other molecular prognostic factors. For example, patients 1 and 5 had higher MDR1 expression (data not shown).
In conclusion, BMI-1 could be an excellent marker of prognosis in AML. It could also be useful for designing therapy for AML patients.
